Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11044140 | PMC |
| http://dx.doi.org/10.3389/ti.2024.12628 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biopsy-Proven T-Cell Mediated Rejection After Belatacept Rescue Conversion: A Multicenter Retrospective Study.
Transpl Int
December 2024
Department of Nephrology, Kidney Transplantation and Hemodialysis, Rouen University Hospital, Rouen, France.
After kidney transplantation, conversion to belatacept is a promising alternative in patients with poor graft function or intolerance to calcineurin inhibitors. The risk of acute rejection has not been well described under these conditions. Here we present a retrospective multicenter study investigating the occurrence of acute rejection after conversion in 901 patients (2011-2021).
View Article and Find Full Text PDFAbatacept inhibits Th17 differentiation and mitigates α-synuclein-induced dopaminergic dysfunction in mice.
Mol Psychiatry
August 2024
School of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Parkinson's disease (PD) is a multifaceted disease characterized by degeneration of nigrostriatal dopaminergic neurons, which results in motor and non-motor dysfunctions. Accumulation of α-synuclein (αSYN) in Lewy bodies is a key pathological feature of PD. Although the exact cause of PD remains unknown, accumulating evidence suggests that brain infiltration of T cells plays a critical role in the pathogenesis of disease, contributing to neuroinflammation and dopaminergic neurodegeneration.
View Article and Find Full Text PDFBelatacept and carfilzomib-based treatment for antibody-mediated rejection in a sensitized nonhuman primate kidney transplantation model.
Front Transplant
September 2023
Department of Surgery, Duke Transplant Center, Duke University Medical Center, Durham, NC, United States.
Introduction: One-third of HLA-incompatible kidney transplant recipients experience antibody mediated rejection (AMR) with limited treatment options. This study describes a novel treatment strategy for AMR consisting of proteasome inhibition and costimulation blockade with or without complement inhibition in a nonhuman primate model of kidney transplantation.
Methods: All rhesus macaques in the present study were sensitized to maximally MHC-mismatched donors by two sequential skin transplants prior to kidney transplant from the same donor.
Belatacept Rescue Therapy in the Early Period After Simultaneous Kidney-Pancreas Transplantation.
Transpl Int
April 2024
Department of Nephrology and Organ Transplantation, Toulouse University Hospital, Toulouse, France.
Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial.
Lancet Rheumatol
December 2023
Université de Bretagne Occidentale (Univ Brest), CHU Brest, INSERM (U1227), Brest, France.
Background: Medium-dose glucocorticoids can improve symptoms in nearly all patients with polymyalgia rheumatica. According to its good safety profile, abatacept could be used instead of glucocorticoids in early polymyalgia rheumatica. We aimed to determine whether the efficacy of abatacept is sufficient to justify larger studies in early polymyalgia rheumatica.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!